These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32442208)

  • 1. Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease.
    Dekker SEI; Verhoeven A; Soonawala D; Peters DJM; de Fijter JW; Mayboroda OA;
    PLoS One; 2020; 15(5):e0233213. PubMed ID: 32442208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary biomarkers at early ADPKD disease stage.
    Petzold K; Poster D; Krauer F; Spanaus K; Andreisek G; Nguyen-Kim TD; Pavik I; Ho TA; Serra AL; Rotar L
    PLoS One; 2015; 10(4):e0123555. PubMed ID: 25875363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Change in Urinary Myoinositol/Citrate Ratio Associates with Progressive Loss of Renal Function in ADPKD Patients.
    Dekker SEI; Verhoeven A; Frey D; Soonawala D; Peters DJM; Mayboroda OA; de Fijter JW;
    Am J Nephrol; 2022; 53(6):470-480. PubMed ID: 35613556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIM-1 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease: HALT-PKD Results.
    Griffin BR; You Z; Noureddine L; Gitomer B; Perrenoud L; Wang W; Chonchol M; Jalal D;
    Am J Nephrol; 2020; 51(6):473-479. PubMed ID: 32541154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC; Kang AY; Jang JY; Kim H; Han M; Oh KH; Kim SH; Noh JW; Cheong HI; Hwang YH; Ahn C
    BMC Nephrol; 2015 Jun; 16():86. PubMed ID: 26092580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in tubular biomarkers with dietary intervention and metformin in patients with autosomal dominant polycystic kidney disease: a post-hoc analysis of two clinical trials.
    Wang W; You Z; Steele CN; Gitomer B; Chonchol M; Nowak KL
    BMC Nephrol; 2024 Jun; 25(1):206. PubMed ID: 38918734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of arginine vasopressin surrogate marker urinary copeptin with severity of autosomal dominant polycystic kidney disease (ADPKD).
    Nakajima A; Lu Y; Kawano H; Horie S; Muto S
    Clin Exp Nephrol; 2015 Dec; 19(6):1199-205. PubMed ID: 25715868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age- and height-adjusted total kidney volume growth rate in autosomal dominant polycystic kidney diseases.
    Higashihara E; Yamamoto K; Kaname S; Okegawa T; Tanbo M; Yamaguchi T; Shigemori K; Miyazaki I; Yokoyama K; Nutahara K
    Clin Exp Nephrol; 2019 Jan; 23(1):100-111. PubMed ID: 30097754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
    Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
    Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the Mayo Imaging Classification System for Predicting Kidney Outcomes in ADPKD.
    Bais T; Geertsema P; Knol MGE; van Gastel MDA; de Haas RJ; Meijer E; Gansevoort RT;
    Clin J Am Soc Nephrol; 2024 May; 19(5):591-601. PubMed ID: 38407866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kidney volume and function in autosomal dominant polycystic kidney disease.
    Higashihara E; Nutahara K; Okegawa T; Shishido T; Tanbo M; Kobayasi K; Nitadori T
    Clin Exp Nephrol; 2014 Feb; 18(1):157-65. PubMed ID: 23864346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression.
    Heida JE; Gansevoort RT; Messchendorp AL; Meijer E; Casteleijn NF; Boertien WE; Zittema D;
    Clin J Am Soc Nephrol; 2021 Feb; 16(2):204-212. PubMed ID: 33504546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression.
    Messchendorp AL; Meijer E; Boertien WE; Engels GE; Casteleijn NF; Spithoven EM; Losekoot M; Burgerhof JGM; Peters DJM; Gansevoort RT;
    Kidney Int Rep; 2018 Mar; 3(2):291-301. PubMed ID: 29725632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
    Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
    BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease.
    Torres VE; Abebe KZ; Schrier RW; Perrone RD; Chapman AB; Yu AS; Braun WE; Steinman TI; Brosnahan G; Hogan MC; Rahbari FF; Grantham JJ; Bae KT; Moore CG; Flessner MF
    Kidney Int; 2017 Feb; 91(2):493-500. PubMed ID: 27993381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD.
    Knol MGE; Bais T; Geertsema P; Connelly MA; Bakker SJL; Gansevoort RT; van Gastel MDA;
    Nephrol Dial Transplant; 2024 Apr; 39(5):838-847. PubMed ID: 37974030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma metabolites and lipids associate with kidney function and kidney volume in hypertensive ADPKD patients early in the disease course.
    Kim K; Trott JF; Gao G; Chapman A; Weiss RH
    BMC Nephrol; 2019 Feb; 20(1):66. PubMed ID: 30803434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD).
    Uchiyama K; Mochizuki T; Shimada Y; Nishio S; Kataoka H; Mitobe M; Tsuchiya K; Hanaoka K; Ubara Y; Suwabe T; Sekine A; Nutahara K; Tsuruya K; Ishimura E; Nakatani S; Sofue T; Tanaka S; Narita I; Maruyama S; Horie S; Muto S
    Clin Exp Nephrol; 2021 Sep; 25(9):970-980. PubMed ID: 33928479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.